Close Menu

NEW YORK, July 10 - ActivX Biosciences has raised $20 million in a private placement to develop the company's chemistry-based proteomics platform, the company said Tuesday. 

In addition to Oxford Bioscience Partners, who led the placement, new investors in the company include Vulcan Ventures, CIT Venture Capital, and Novo A/S. Frazier & Company and ProQuest Investments are existing investors in the company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.